Mr. Daniel Carcillo reports

WESANA HEALTH ANNOUNCES VOTING RESULTS OF AGSM

All matters put forward at Wesana Health Holdings Inc.'s annual general and special meeting of shareholders held on June 9, 2023, were duly approved by the requisite majority of votes cast at the AGSM.

AGSM results

A total of approximately 80 per cent of the votes entitled by the outstanding shares of the company were present and voted at the AGSM by shareholders and proxyholders. The following resolutions were approved by over 99 per cent of votes cast:

• Election of all director nominees to the board of directors for the ensuing year;
• Appointment of MNP LLP as the auditor of the company for the ensuing year;
• Passing of a special resolution approving the sale by Wesana Health Inc., a subsidiary of the company, of its right and interest in the SANA-013 development related assets and any other applicable related assets pursuant to the terms of the asset purchase agreement among the company, Lucy Scientific Discovery Inc. (Nasdaq: LSDI), Lucy Scientific Discovery USA Inc. and Wesana Health Inc. dated March 20, 2023, as more particularly described and set forth in the management information circular of the company dated May 9, 2023. The transaction is expected to close this month (June, 2023), subject to and following the satisfaction (or waiver as permitted) of the conditions precedent to the transaction.

About Wesana Health Holdings Inc.

Wesana Health is a data-driven life science company pioneering drug development through its lead candidate SANA-013. Targeting major depressive disorder as the lead indication, SANA-013 utilizes proprietary drug delivery protocols and a novel combination therapy. Wesana is composed of leaders from the scientific, research and medical industries driven by a common goal of improving the lives of millions of people globally suffering from mental health indications.

We seek Safe Harbor.